SHARE

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) has announced the addition of Thomas Jefferson University hospital, as the latest site of it’s INSPIRE study on the Neuro-Spinal Scaffold. The program is targeted at improving the condition of patients with Thoracic AIS A spinal cord injury. The Thomas Jefferson University hospital is the third addition this month, to the list of sites for the INSPIRE study. The other two included Vidant Medical Center and University of Louisville Hospital.

The Thomas Jefferson University hospital is known to be one of the 14 Spinal Cord Injury model centers, in affiliation with Magee Rehabilitation Hospital. Added to this, the principle investigator at the site would be James Harrop M.D. He is Co-Director of the Adult Reconstructive Spine and also a professor of neurosurgery. Similarly, the principle investigator at Vidant Medical center is, Stuart Lee M.D.

Much like the Thomas Jefferson University hospital, the University of Louisville has some advantages. The hospital serves as a Data Management Center and mostly works in collaboration with Christopher and Dana Reeve Foundation. The foundation currently operates the largest research network on spinal cord injury, in the country. Furthermore, the principle investigator at this site would be Maxwell Boakye M.D, M.P.H.

The Neur-Spinal Scaffold study, INSPIRE, had just one patient, at the beginning of 2015. However, as the year progressed, a total of 5-patients had been enrolled in the study. The company aims to conduct trials on as many as 20 patients in total. Invivo is set to achieve this target, during the current year. Added to this, the company also expects to expand the network of its clinical sites to UK and Canada. Furthermore, Invivo also plans to initiate a study on cervical spinal cord injury and some progress with its Bioengineered neural trials. Currently, the company has several sites for conducting trials of the INSPIRE study, across the US.

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) gained 0.51% during the March 8 trading session, to reach a close at $9.85.

LEAVE A REPLY